Mechanisms in failure of infliximab for Crohn's disease

Lancet

Volumn 356, Issue 9240, 2000, Pages 1475-1479

  Nikolaus, Susanna ^a   Raedler, Andreas ^b   Kühbacher, Tanja ^a   Sfikas, Nicolaos ^a   Fölsch, Ulrich R ^a   Schreiber, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Tabea Centre for Inflammatory Bowel Disease   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; MESALAZINE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; COLON BIOPSY; COLON CROHN DISEASE; COMPLEMENT ACTIVATION; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION; TREATMENT FAILURE; WOUND HEALING;

EID: 0034727474     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02871-3     Document Type: Article

References (40)

1. Disease activity courses in a regional cohort of Crohn's disease patients
2. Oral budesonide as maintenance treatment for Crohn's disease: A placebo controlled dose-ranging study
3. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
4. National Cooperative Crohn's Disease Study: Results of drug treatment
5. Frequency of glucocorticoid resistance and dependency in Crohn's disease
6. A controlled double blind study of azathioprine in the management of Crohn's disease
7. Tumor necrosis factor a, interleukin-1β and interleukin 6 expression in inflammatory bowel disease
8. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification
9. Enhanced secretion of tumor necrosis factor-alpha, 1L-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
10. Tumor necrosis factor-a and interleukin 1β in relapse of Crohn's disease
11. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor a gene in primary macrophages
12. NF-kappa B subunit specific regulation in the interleukin-8 promoter
13. NF-kappa B: A pleiotropic mediator of inducible and tissue-specific gene control
14. The NF-KB and I-KB proteins: New discoveries and insights
15. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
16. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric antibody (cA2)
17. A short term study of chimeric monoclonal antibody cA2 tumor necrosis factor-a for Crohn's disease
18. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
19. Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve steroid dependent chronic active Crohn's disease in a pilot study
20. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
21. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
22. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
23. Chimeric anti-TNF-a monoclonal antibody, cA2, binds recombinant transmembrane TNF-a and activates immune effector functions
24. A novel form of TNF/Cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF
25. Development of a Crohn's disease activity index. National Cooperative Crohn's disease Study
26. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI)
27. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease
28. Tumor necrosis factor and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB
29. An interleukin-4 induced transcription factor: IL-4 Stat
30. Activation of nuclear factor κB in inflammatory bowel disease
31. Tumour necrosis factor alpha in stools as a marker of intestinal inflammation
32. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa
33. Role of transcriptional activation by IκB in mediation of immunosuppression by glucocorticoids
34. Immunopharmacology of 5-aminosalicylic acid and glucocorticoids in the therapy of inflammatory bowel disease
35. Recombinant human interleukin-10 for the treatment of chronic active Crohn's diease
36. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappa B activation in mouse colonocytes
37. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity
38. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
39. Infliximab exerts anti-inflammatory capacity in IBD by induction of apoptosis in monocytes
40. Evaluation of TNF microsatellites and SNPs in a cohort of chronic active, therapy refractory Crohn's disease patients treated with anti TNF-alpha